<?xml version="1.0" encoding="UTF-8"?><article xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="pmc-domain-id">4181</journal-id><journal-id journal-id-type="pmc-domain">cimb</journal-id><journal-title-group><journal-title>Current Issues in Molecular Biology</journal-title><abbrev-journal-title>Curr Issues Mol Biol</abbrev-journal-title></journal-title-group><publisher><publisher-name>Multidisciplinary Digital Publishing Institute (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12468367</article-id><article-id pub-id-type="pmcaid">12468367</article-id><article-id pub-id-type="pmcaiid">12468367</article-id><article-id pub-id-type="pmid">41020813</article-id><article-id pub-id-type="doi">10.3390/cimb47090691</article-id><title-group><article-title>Correlation Between In Silico Docking/Simulation Results and In Vitro MAGL Inhibition Potency of Selected Triterpenes</article-title></title-group><contrib-group content-type="author"><contrib><name name-style="western"><surname>Masocha</surname><given-names initials="W">Willias</given-names></name><xref ref-type="aff" rid="af1-cimb-47-00691">1</xref><xref rid="c1-cimb-47-00691" ref-type="author-notes">*</xref></contrib><contrib><name name-style="western"><surname>Khedr</surname><given-names initials="MA">Mohammed A</given-names></name><xref ref-type="aff" rid="af2-cimb-47-00691">2</xref></contrib></contrib-group><contrib-group content-type="editor"><contrib><name name-style="western"><surname>Zou</surname><given-names initials="Q">Quan</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cimb-47-00691"><label>1</label>Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Kuwait City 13110, Kuwait</aff><aff id="af2-cimb-47-00691"><label>2</label>Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt; mohammed_abdou0@yahoo.com</aff><author-notes><fn id="c1-cimb-47-00691"><label>*</label><p>Correspondence: <email>willias.masocha@ku.edu.kw</email>; Tel.: +965-2463-6034</p></fn></author-notes><pub-date><day>27</day><month>8</month><year>2025</year></pub-date><volume>47</volume><issue>9</issue><fpage>691</fpage><page-range>691</page-range><pub-history><event event-type="pmc-release"><date><day>27</day><month>9</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© 2025 by the authors.</copyright-statement><license><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cimb-47-00691.pdf" content-type="pmc-pdf"><?cloudpmc-path ba25/12468367/137e937cff0d/cimb-47-00691.pdf?><?cloudpmc-bucket app?><?size 2703671?></self-uri><abstract id="abstract1"><title>Abstract</title><p>Monoacylglycerol lipase (MAGL) degrades the endocannabinoid 2-arachidonyl glycerol. MAGL inhibitors, such as the triterpene pristimerin, alleviate neuropathic pain in animal models. In silico studies were carried out using SwissDock, PyRx-0.8 and CB-Dock2, to check if they correlated with the in vitro MAGL inhibition potency of various triterpenes. In terms of affinity, free energy of binding and docking scores to MAGL, pristimerin (52.75, −9.32, −10.83, and −11.5 kcal/mol) was better than euphol (44.86, −8.49, −9.56, and −10.7 kcal/mol), which in turn was better than β-amyrin (35.17, −7.37, −8.21, and −8.8 kcal/mol). Finally, β-amyrin was better than or equal to α-amyrin (35.10, −7.19, −7.95, and −8.6 kcal/mol). In molecular dynamic simulations (MDSs), pristimerin exhibited the highest stability and reached the steady state after 20 ns with the lowest root mean square fluctuation (RMSF) at the binding site, compared to the triterpenes. The reported half maximal inhibitory concentration (IC<sub>50</sub>) values of recombinant human and rat MAGL inhibition were in the following order: α-amyrin &gt; β-amyrin &gt; euphol &gt; pristimerin. Linear regression analysis showed that the affinity, free energy of binding, and docking scores significantly correlated with the IC<sub>50</sub> of MAGL inhibition. Amongst the triterpenes studied, pristimerin was the most potent inhibitor of MAGL and also had the highest affinity in the in silico studies. Thus, molecular docking and MDS results correlated with the potency of triterpenes inhibiting MAGL activity in vitro and could be used for screening of triterpenes prior to experimental validation.</p><sec id="kwd-group1" sec-type="kwd-group" disp-level="2"><p><bold>Keywords:</bold> MAGL inhibition, endocannabinoids, molecular docking, molecular dynamic simulation, triterpenes, pristimerin, in vitro, screening, correlation, 2-arichdonyl glycerol</p></sec></abstract><custom-meta-group><custom-meta><meta-name>status</meta-name><meta-value>released</meta-value></custom-meta><custom-meta><meta-name>display-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>is-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>is-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>is-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>is-journal-matter</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>is-scanned</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>is-retracted</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="article-notes"><sec id="historyarticle-meta1" sec-type="history" disp-level="2"><p>Received 2025 Jul 23; Revised 2025 Aug 17; Accepted 2025 Aug 19; Collection date 2025 Sep.</p></sec></notes></front><body><sec id="sec1-cimb-47-00691" disp-level="1"><title>1. Introduction</title><p>Monoacylglycerol lipase (MAGL) is an enzyme that degrades 2-arachidonoylglycerol (2-AG), which is an endocannabinoid [<xref rid="B1-cimb-47-00691" ref-type="bibr">1</xref>,<xref rid="B2-cimb-47-00691" ref-type="bibr">2</xref>,<xref rid="B3-cimb-47-00691" ref-type="bibr">3</xref>]. 2-AG is the most abundant endocannabinoid, an agonist at both cannabinoid type 1 (CB1) and CB2 receptors and is involved in various physiological functions including retrograde signaling in regulation of synaptic transmission and plasticity, inflammation and pain sensation [<xref rid="B4-cimb-47-00691" ref-type="bibr">4</xref>,<xref rid="B5-cimb-47-00691" ref-type="bibr">5</xref>]. It is produced on-demand and rapidly metabolized by MAGL [<xref rid="B4-cimb-47-00691" ref-type="bibr">4</xref>,<xref rid="B6-cimb-47-00691" ref-type="bibr">6</xref>]. It has recently been shown that there is a deficiency in 2-AG in the paw skin of mice with paclitaxel-induced mechanical allodynia, which is a model of chemotherapy-induced neuropathic pain [<xref rid="B7-cimb-47-00691" ref-type="bibr">7</xref>]. This suggests that inhibition of MAGL could increase the amount of 2-AG and alleviate paclitaxel-induced mechanical allodynia. Indeed, treatment with MAGL inhibitors JZL184, MJN110, and pristimerin alleviated and prevented paclitaxel-induced mechanical allodynia [<xref rid="B7-cimb-47-00691" ref-type="bibr">7</xref>,<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>,<xref rid="B9-cimb-47-00691" ref-type="bibr">9</xref>].</p><p>The first characterized natural compounds that inhibited MAGL activity are the triterpenes, pristimerin and euphol [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. They inhibit the activity of MAGL in a reversible manner. Pristimerin inhibited MAGL with higher potency than euphol [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. Other studies have shown that other triterpenes such as α-amyrin and β-amyrin inhibit MAGL activity in vitro but with lower potency or effect than pristimerin [<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]. It has also been shown recently that pristimerin inhibits MAGL activity in purified human MAGL in vitro and in the brain and paw skin tissues of mice [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>]. Pristimerin also prevented the development of paclitaxel-induced mechanical allodynia [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>].</p><p>Triterpenes are bioactive secondary metabolites found in various herbal plants used in ethnomedicine such as <italic>Swertia mileensis, Euphorbia kansui, Alismatis rhizome, Panax ginseng</italic> C. A. Meyer [<xref rid="B12-cimb-47-00691" ref-type="bibr">12</xref>,<xref rid="B13-cimb-47-00691" ref-type="bibr">13</xref>,<xref rid="B14-cimb-47-00691" ref-type="bibr">14</xref>,<xref rid="B15-cimb-47-00691" ref-type="bibr">15</xref>,<xref rid="B16-cimb-47-00691" ref-type="bibr">16</xref>]. They have been found to have many biological effects including anticancer, osteogenic, antidiabetic, analgesic, and anti-inflammatory activities, amongst many others [<xref rid="B12-cimb-47-00691" ref-type="bibr">12</xref>,<xref rid="B13-cimb-47-00691" ref-type="bibr">13</xref>,<xref rid="B14-cimb-47-00691" ref-type="bibr">14</xref>,<xref rid="B15-cimb-47-00691" ref-type="bibr">15</xref>,<xref rid="B16-cimb-47-00691" ref-type="bibr">16</xref>]. Various studies have also shown that triterpenes have antinociceptive activities and can alleviate pain symptoms associated with inflammation and neuropathic pain [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>,<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>,<xref rid="B17-cimb-47-00691" ref-type="bibr">17</xref>,<xref rid="B18-cimb-47-00691" ref-type="bibr">18</xref>]. Some of the antinociceptive and antiallodynic activities of these triterpenes, such as β-amyrin and pristimerin, have been attributed to their inhibitory effects on MAGL activity, leading to an increase in the levels of 2-AG [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>,<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>].</p><p>There is a possibility that other triterpenes found in plants used in ethnomedicine inhibit MAGL activity. To reduce the cost and time of evaluating triterpene activity in in vitro and in vivo experiments, it would be necessary to evaluate them in silico to enable selection of triterpenes with the best MAGL inhibitory activities. Molecular docking has been used to evaluate the interaction of triterpenes, as well as other molecules, with MAGL [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>,<xref rid="B19-cimb-47-00691" ref-type="bibr">19</xref>,<xref rid="B20-cimb-47-00691" ref-type="bibr">20</xref>,<xref rid="B21-cimb-47-00691" ref-type="bibr">21</xref>]. Because of the presence of freely available software and servers, molecular docking is a cheap and easy way to evaluate the affinity of ligands to their protein targets [<xref rid="B22-cimb-47-00691" ref-type="bibr">22</xref>,<xref rid="B23-cimb-47-00691" ref-type="bibr">23</xref>,<xref rid="B24-cimb-47-00691" ref-type="bibr">24</xref>]. Molecular dynamics simulations (MDSs) provide computational validation of molecular docking studies. However, no studies have been carried out that correlate the affinity of triterpenes to MAGL obtained by molecular docking and MDS to the inhibitory effects of triterpenes on MAGL activity in vitro. If there is a correlation between affinity and free energy binding scores of triterpenes to MAGL and their potency of inhibiting MAGL in vitro, it would make it easy to screen the triterpenes.</p><p>In this study, the free energy of binding of triterpenes on MAGL was computed. The affinity (kcal/mol) was calculated using SwissDock server, and docking was carried out by using a publicly available docking server, CB-Dock2, from the Young Cao Lab, [<xref rid="B23-cimb-47-00691" ref-type="bibr">23</xref>] and also by PyRx-0.8. These were compared with their in vitro inhibition of MAGL activity. MDSs were carried out to validate the molecular docking results. The triterpenes that were evaluated were chosen based on the presence of the IC<sub>50</sub> values of MAGL inhibition in previous studies in comparison to pristimerin [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>,<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>].</p></sec><sec id="sec2-cimb-47-00691" disp-level="1"><title>2. Materials and Methods</title><sec id="sec2dot1-cimb-47-00691" disp-level="2"><title>2.1. Literature Search</title><p>A search of articles in the U.S. National Library of Medicine, Washington, DC (MED-LINE-PubMed) was conducted for this study up to 21 June 2024. The following keywords were proposed and searched for in PubMed: “pristimerin”, “triterpene”, “euphol’, “monoacylglycerol lipase”, “inhibitor”, and “inhibition”. Six searches were carried out using different combinations of the keywords or phrases (“pristimerin” OR “euphol” OR “triterpene”) AND (“monoacylglycerol lipase”) AND (“inhibitor” OR “inhibition”).</p><p>Only primary research articles that reported the evaluation of the inhibition of MAGL activity, and the IC<sub>50</sub>, by triterpenes (including pristimerin and/or euphol) were included. Review articles were excluded as well as articles that did not evaluate MAGL inhibition by pristimerin and/or euphol.</p></sec><sec id="sec2dot2-cimb-47-00691" disp-level="2"><title>2.2. Molecular Docking and Molecular Dynamics Simulations</title><p>The three-dimensional (3D) structures of the triterpenes α-amyrin (PubChem CID 73170), β-amyrin (PubChem CID 73145), euphol (PubChem CID 441678), and pristimerin (Pub-Chem CID 159516) were downloaded from PubChem database in .sdf 3D conformer format (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link>, accessed on 15 June 2024). The X-ray crystal structure of human MAGL in complex with an inhibitor, compound 3l (PDB id: 5ZUN), was retrieved from Protein Data Bank (PDB, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rcsb.org/" ext-link-type="uri">https://www.rcsb.org/</ext-link>, accessed on 19 June 2024), in .pdb format.</p><p>Similar to our recent study [<xref rid="B25-cimb-47-00691" ref-type="bibr">25</xref>], CB-Dock2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cadd.labshare.cn/cb-dock2/index.php" ext-link-type="uri">https://cadd.labshare.cn/cb-dock2/index.php</ext-link>, accessed on 9 August 2024), a publicly available docking server from the Yang Cao Lab was used for molecular docking using the auto blind docking option, as described previously [<xref rid="B23-cimb-47-00691" ref-type="bibr">23</xref>]. The docked protein–ligand complexes were downloaded. The lowest Vina scores (highest binding affinity), based on the latest AutoDock Vina, as well as the contact residues in the MAGL cavity for each compound were obtained.</p><p>The studied compounds and the protein were prepared for docking. The free energy of binding was computed, and the affinity (kcal/mol) was calculated using SwissDock server [<xref rid="B26-cimb-47-00691" ref-type="bibr">26</xref>,<xref rid="B27-cimb-47-00691" ref-type="bibr">27</xref>]. Docking was carried out by PyRx-0.8 [<xref rid="B28-cimb-47-00691" ref-type="bibr">28</xref>]. SwissDock and PyRx-0.8 also utilized AutoDock tools and AutoDock Vina. CB-Dock2 and PyRx-0.8 were chosen for docking because they both utilize AutoDock Vina for validation of the docking process, and also because of our experience from previous studies [<xref rid="B25-cimb-47-00691" ref-type="bibr">25</xref>,<xref rid="B29-cimb-47-00691" ref-type="bibr">29</xref>].</p><p>The affinity, free energy of binding, and docking scores by both PyRx-0.8 and CB-Dock2 (AutoDock vina scores) of the triterpenes were used for comparison of the triterpenes.</p><p>Preliminary MDSs were conducted for the best docking pose for the four ligand–MAGL complexes to enable RMSF calculation. The best conformation from each docking process was kept inside the active site. All hydrogens were added, and energy minimization was computed. The solvent molecules that were in the system were deleted before solvation and salt atoms were added to ensure complete neutralization of the system. Solvent atoms were added to surround the system in a spherical shape. The protein–ligand complex was surrounded by a sphere shape of solvent (water) and NaCl was used as a salt to neutralize the charged system. Amber12: EHT was selected as an all-atom forcefield. All bonds, van der Waals, electrostatics, and restraints were enabled. Energy minimization was performed. Root mean square deviation gradient was 1.0. Start time was zero. The MDS protocol was carried out using NPA (Nose–Poincare–Andersen) as a method for solving the equation of motion. Temperature was 300 K and time scale was 50 ns.</p></sec><sec id="sec2dot3-cimb-47-00691" disp-level="2"><title>2.3. Correlation of Affinity, Free Energy of Binding, and Docking Scores and IC<sub>50</sub> of MAGL Inhibition Data from In Vitro Studies</title><p>The GraphPad Prism software (version 10.3) was used to assess the association between the affinity, free energy of binding, and docking scores by both PyRx-0.8 and CB-Dock2 (AutoDock vina scores) of the triterpenes and their in vitro IC<sub>50</sub> of MAGL inhibition data, obtained from studies by King and colleagues and Chicca and colleagues [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>,<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>], using simple linear regression analyses.</p></sec><sec id="sec2dot4-cimb-47-00691" disp-level="2"><title>2.4. In Silico Prediction of the Pharmacokinetic Parameters</title><p>All prediction was carried out using pkCSM (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biosig.lab.uq.edu.au/pkcsm/" ext-link-type="uri">https://biosig.lab.uq.edu.au/pkcsm/</ext-link>). The databases of experimentally measured ADMET properties are widely available. pkCSM applied a graph-based structural signature to predict ADMET properties of novel compounds when compared to the reported compounds in the databases.</p></sec></sec><sec id="sec3-cimb-47-00691" disp-level="1"><title>3. Results</title><sec id="sec3dot1-cimb-47-00691" disp-level="2"><title>3.1. Articles That Reported the Evaluation of the Inhibition of MAGL Activity by Triterpenes, Including Euphol and/or Pristimerin</title><p>The PubMed searches produced twenty-four articles, which were reduced to eight articles after the removal of duplicates. Five articles were excluded for several reasons, detailed in <xref rid="cimb-47-00691-t0A1" ref-type="table">Table A1</xref> and <xref rid="cimb-47-00691-f0A1" ref-type="fig">Figure A1</xref>, which shows the study flow information. Thus, three articles from PubMed searches fit the inclusion criteria. King and colleagues studied the inhibition of MAGL activity by pristimerin and euphol on purified recombinant rat MAGL and non-purified (cell lysates of MAGL-transfected HeLa cells) and found that pristimerin was more potent than euphol in inhibiting MAGL activity; see <xref rid="cimb-47-00691-t001" ref-type="table">Table 1</xref> [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. Chicca and colleagues studied the inhibition of MAGL activity by α-amyrin, β-amyrin and pristimerin on purified recombinant human MAGL and found that pristimerin was more potent than β-amyrin, and the latter was more potent than α-amyrin (<xref rid="cimb-47-00691-t001" ref-type="table">Table 1</xref>; [<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]). We, Al-Romaiyan and Masocha, studied the inhibition of MAGL activity by betulinic acid, cucurbitacin B, euphol and pristimerin on recombinant human MAGL, non-purified mouse brain and non-purified mouse paw skin [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>]. Only pristimerin had a concentration-dependent inhibition of recombinant human MAGL, as well as on non-purified mouse brain and non-purified mouse paw skin activity. Similar to the study by King and colleagues [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>], Al-Romaiyan and Masocha found that pristimerin had more effect against purified recombinant MAGL than non-purified MAGL [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>]. At a fixed concentration of 1 µM, pristimerin (50.3150 ± 4.0452%) inhibited recombinant human MAGL more than euphol (15.932 ± 8.654%) [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>], which is in line with the results from previous studies [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>].</p><table-wrap id="cimb-47-00691-t001" position="float"><?disp-level 3?><label>Table 1</label><caption><p>IC<sub>50</sub> values of α-amyrin, β-amyrin, euphol and pristimerin inhibition of MAGL activity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Triterpene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source/Type of MAGL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-Amyrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9300 ± 1200 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant human MAGL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">β-Amyrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2800 ± 500 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant human MAGL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Euphol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">315 ± 1 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified recombinant rat MAGL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">882 ± 78 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-purified (cell lysates of MAGL-transfected HeLa cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Pristimerin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93 ± 8 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified recombinant rat MAGL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">398 ± 68 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-purified (cell lysates of MGL-transfected HeLa cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">204 ± 16.2 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant human MAGL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant human MAGL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1600 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-purified mouse brain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">596 nM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-purified Mouse paw skin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="fn2"><p>* IC<sub>50</sub> values from different studies were obtained under different assay conditions.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3dot2-cimb-47-00691" disp-level="2"><title>3.2. Molecular Docking and Molecular Dynamic Simulations of Triterpenes on MAGL</title><p>The results of the molecular docking of the four triterpenes, α-amyrin, β-amyrin, euphol, and pristimerin on MAGL using CB-Dock2 are shown in <xref rid="cimb-47-00691-t002" ref-type="table">Table 2</xref> and <xref rid="cimb-47-00691-f001" ref-type="fig">Figure 1</xref>. All four triterpenes docked to the same cavity of MAGL and similar contact residues, with high affinity. The affinity of the triterpenes based on Vina scores was pristimerin (−11.5 kcal/mol) &gt; euphol (−10.7 kcal/mol) &gt; β-amyrin (−8.8 kcal/mol) ≥ α-amyrin (−8.6 kcal/mol). Thus, pristimerin had the highest binding affinity, better than euphol, α-amyrin and β-amyrin. The ligands bound to nearly the same amino acid contact residues (high-lighted in red). α-amyrin, β-amyrin and euphol bound to four other amino acids (high-lighted in turquoise), to which pristimerin did not bind.</p><table-wrap id="cimb-47-00691-t002" position="float"><?disp-level 3?><label>Table 2</label><caption><p>Comparison of the best CB-Dock2 molecular docking Vina scores (kcal/mol) of α-amyrin, β-amyrin, euphol, and pristimerin on MAGL (5ZUN). Cavity volume (1904, Å3), center (x, y, z; 10, 17, −6), and docking size (x, y, z; 23, 23, 23).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Triterpene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vina Score (kcal/mol)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Contact Residues</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">α-Amyrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GLY50 ALA51 MET88 SER122 MET123 LEU148 ALA151 ASN152 GLU154 SER155 ALA156 THR158 PHE159 SER176 GLY177 PRO178 ILE179 ASP180 VAL183 LEU184 LEU205 PHE209 GLY210 LEU213 LEU214 ARG240 LEU241 HIS269</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">β-Amyrin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−8.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GLY50 ALA51 GLY52 HIS121 SER122 MET123 LEU148 ALA151 ASN152 GLU154 SER155 ALA156 THR158 PHE159 SER176 GLY177 PRO178 ILE179 ASP180 SER181 VAL183 LEU184 LEU205 PHE209 GLY210 LEU213 LEU214 VAL217 ARG240 LEU241 CYS242 HIS269</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Euphol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−10.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GLY50 ALA51 MET88 SER122 MET123 LEU148 LEU150 ALA151 ASN152 GLU154 SER155 ALA156 THR158 PHE159 LYS160 SER176 GLY177 PRO178 ILE179 ASP180 VAL183 LEU184 LEU205 PHE209 GLY210 LEU213 LEU214 VAL217 ARG240 LEU241 CYS242 HIS269</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pristimerin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−11.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GLY50 ALA51 MET88 SER122 MET123 LEU148 ALA151 SER155 ALA156 THR158 PHE159 SER176 GLY177 PRO178 ILE179 ASP180 VAL183 LEU184 LEU205 GLY210 LEU213 LEU214 VAL217 ARG240 LEU241</td></tr></tbody></table></table-wrap><fig id="cimb-47-00691-f001" position="float"><?disp-level 3?><label>Figure 1</label><caption><p>Illustration of the molecular docking of triterpenes to MAGL (5ZUN). α-amyrin, β-amyrin, euphol, and pristimerin interact with the same MAGL cavities. The best potential cavity regions on MAGL were detected by a structure-based approach. The interactive visualization for the 3D structure of MAGL with (<bold>A</bold>) α-amyrin, (<bold>B</bold>) β-amyrin, (<bold>C</bold>) euphol, and (<bold>D</bold>) pristimerin bound to the cavity. The receptor, MAGL, was coloured by secondary structure. The docking files have been uploaded to Zenodo. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.16890027" ext-link-type="uri">https://doi.org/10.5281/zenodo.16890027</ext-link>.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="image" xlink:href="cimb-47-00691-g001.jpg"><?cloudpmc-path blobs/ba25/12468367/70fdc58eb8f0/cimb-47-00691-g001.jpg?><?cloudpmc-bucket cdn?><?image-server-status LOAD_COMPLETED?><?original-height 3524?><?original-width 2651?><?scaled-height 1006?><?scaled-width 757?></graphic><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="thumb" xlink:href="cimb-47-00691-g001.gif"><?cloudpmc-path blobs/ba25/12468367/27bf7af31406/cimb-47-00691-g001.gif?><?cloudpmc-bucket cdn?></graphic></alternatives></fig><p>According to the docking scores (<xref rid="cimb-47-00691-t003" ref-type="table">Table 3</xref>), pristimerin had the top ranked affinity (52.75 kcal/mol), free energy of binding (−9.32 kcal/mol), and docking score by both PyRx-0.8 (−10.83 kcal/mol) and CB-Dock2 (−11.5 kcal/mol), which is an excellent computational validation of the results. The main interactions of α-amyrin were the hydrogen bond between -NH2 group of Arg57 and the oxygen atom of -OH group, in addition to another hydrogen bond between Glu53 carboxylic group -C=O and the hydrogen atom of -OH group (<xref rid="cimb-47-00691-f002" ref-type="fig">Figure 2</xref>A). On the other hand, the hydroxyl group of β-amyrin interacted by hydrogen bond formation with Ala267 with possible hydrophobic interactions with Leu241 (<xref rid="cimb-47-00691-f002" ref-type="fig">Figure 2</xref>B). The -OH group plays an important role in euphol’s interactions through the formation of ahydrogen bond with Asp180 and a very good placement and fitting for the alkenyl side chain (<xref rid="cimb-47-00691-f002" ref-type="fig">Figure 2</xref>C). Pristimerin showed a hydrogen bond between -C=O and Ser122 with possible hydrophobic interactions with Leu184, Ile179, Val270, and Tyr194 (<xref rid="cimb-47-00691-f002" ref-type="fig">Figure 2</xref>D).</p><table-wrap id="cimb-47-00691-t003" position="float"><?disp-level 3?><label>Table 3</label><caption><p>Affinity and docking scores obtained using SwissDock, PyRx-0.8 dock, and CB-Dock2. All three virtual screening software/servers utilize AutoDock Vina docking system.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Scores</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">α-Amyrin</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">β-Amyrin</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Euphol</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Pristimerin</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PubChem CID</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73,170</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73,145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">441,678</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">159,516</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Free energy of binding (kcal/mol)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−7.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−7.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−8.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−9.32</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Affinity (kcal/mol)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.86</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PyRx-0.8 dock (kcal/mol)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−7.95</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−8.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−9.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−10.83</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CB-Dock2 (kcal/mol)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−8.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−10.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−11.5</td></tr></tbody></table></table-wrap><fig id="cimb-47-00691-f002" position="float"><?disp-level 3?><label>Figure 2</label><caption><p>The best docking pose for (<bold>A</bold>) α-Amyrin–MAGL complex, (<bold>B</bold>) β-Amyrin–MAGL complex, (<bold>C</bold>) Euphol–MAGL complex, and (<bold>D</bold>) Pristimerin–MAGL complex.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="image" xlink:href="cimb-47-00691-g002.jpg"><?cloudpmc-path blobs/ba25/12468367/21847c9bcfff/cimb-47-00691-g002.jpg?><?cloudpmc-bucket cdn?><?image-server-status LOAD_COMPLETED?><?original-height 1611?><?original-width 2586?><?scaled-height 460?><?scaled-width 738?></graphic><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="thumb" xlink:href="cimb-47-00691-g002.gif"><?cloudpmc-path blobs/ba25/12468367/65f2ecd1baf7/cimb-47-00691-g002.gif?><?cloudpmc-bucket cdn?></graphic></alternatives></fig><p>The compounds studied were subjected to an MDS study over 50 ns. During this period, pristimerin showed the highest stability and reached the steady state after 20 ns with the lowest root mean square fluctuation (RMSF), especially at the binding site (docking site) (<xref rid="cimb-47-00691-f003" ref-type="fig">Figure 3</xref>D), when compared to the other three compounds: α-amyrin, β-amyrin, and euphol (<xref rid="cimb-47-00691-f004" ref-type="fig">Figure 4</xref>).</p><fig id="cimb-47-00691-f003" position="float"><?disp-level 3?><label>Figure 3</label><caption><p>Root mean square fluctuation (RMSF) of (<bold>A</bold>) α-Amyrin–MAGL complex, (<bold>B</bold>) β-Amyrin–MAGL complex, (<bold>C</bold>) Euphol–MAGL complex, and (<bold>D</bold>) Pristimerin–MAGL complex.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="image" xlink:href="cimb-47-00691-g003.jpg"><?cloudpmc-path blobs/ba25/12468367/896ba8cc0c06/cimb-47-00691-g003.jpg?><?cloudpmc-bucket cdn?><?image-server-status LOAD_COMPLETED?><?original-height 1938?><?original-width 3112?><?scaled-height 485?><?scaled-width 778?></graphic><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="thumb" xlink:href="cimb-47-00691-g003.gif"><?cloudpmc-path blobs/ba25/12468367/fbb318243ccf/cimb-47-00691-g003.gif?><?cloudpmc-bucket cdn?></graphic></alternatives></fig><fig id="cimb-47-00691-f004" position="float"><?disp-level 3?><label>Figure 4</label><caption><p>Collective root mean square fluctuation (RMSF) graph of the studied MAGL–ligand complexes.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="image" xlink:href="cimb-47-00691-g004.jpg"><?cloudpmc-path blobs/ba25/12468367/3b7cac11a7bb/cimb-47-00691-g004.jpg?><?cloudpmc-bucket cdn?><?image-server-status LOAD_COMPLETED?><?original-height 1243?><?original-width 2136?><?scaled-height 414?><?scaled-width 712?></graphic><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="thumb" xlink:href="cimb-47-00691-g004.gif"><?cloudpmc-path blobs/ba25/12468367/8e7f68517fb9/cimb-47-00691-g004.gif?><?cloudpmc-bucket cdn?></graphic></alternatives></fig></sec><sec id="sec3dot3-cimb-47-00691" disp-level="2"><title>3.3. Comparison of Affinity, Free Energy of Binding and Docking Scores by Both PyRx-0.8, and CB-Dock2 and IC<sub>50</sub> of MAGL Inhibition Data from In Vitro Studies</title><p>Free energy of binding had a significantly negative correlation with affinity and positive correlation with docking scores (<xref rid="cimb-47-00691-f005" ref-type="fig">Figure 5</xref>A,B). Affinity had a significantly negative correlation with docking scores (<xref rid="cimb-47-00691-f005" ref-type="fig">Figure 5</xref>C). The PyRx-0.8 and CB-Dock2 docking scores had a significantly positive correlation (<xref rid="cimb-47-00691-f005" ref-type="fig">Figure 5</xref>D). This was an excellent computational validation of the results of the different methods and software.</p><fig id="cimb-47-00691-f005" position="float"><?disp-level 3?><label>Figure 5</label><caption><p>Relationships of α-amyrin, β-amyrin, euphol and pristimerin scores on interaction with MAGL for affinity, free energy of binding, and docking score by both PyRx-0.8 and CB-Dock2. Correlation of (<bold>A</bold>) affinity and free energy of binding, (<bold>B</bold>) docking scores and free energy of binding, (<bold>C</bold>) affinity and docking scores, and (<bold>D</bold>) PyRx-0.8 dock and CB-Dock2 docking scores. Simple linear regression analyses performed using GraphPad Prism software (version 10.3). The x- and y-axes represent predicted values.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="image" xlink:href="cimb-47-00691-g005.jpg"><?cloudpmc-path blobs/ba25/12468367/86f4878a23c0/cimb-47-00691-g005.jpg?><?cloudpmc-bucket cdn?><?image-server-status LOAD_COMPLETED?><?original-height 1793?><?original-width 2646?><?scaled-height 512?><?scaled-width 756?></graphic><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="thumb" xlink:href="cimb-47-00691-g005.gif"><?cloudpmc-path blobs/ba25/12468367/9bc92ec7fb70/cimb-47-00691-g005.gif?><?cloudpmc-bucket cdn?></graphic></alternatives></fig><p>Molecular docking scores with CB-Dock2 and PyRx-0.8 showed that pristimerin had higher binding affinity (docking scores of −11.5 and −10.83 kcal/mol, respectively) than euphol (docking scores of −10.7 and −9.56 kcal/mol). The binding affinity of the two triterpenes significantly correlated with the IC<sub>50</sub> of MAGL inhibition data (<italic>p</italic> &lt; 0.0001) from in vitro studies [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]: 93 ± 8 nM for pristimerin and 315 ± 1 nM for euphol on purified recombinant rat MAGL (<xref rid="cimb-47-00691-f006" ref-type="fig">Figure 6</xref>A,D), and 398 ± 68 nM for pristimerin and 882 ± 78 nM for euphol on non-purified HeLa cell MAGL (<xref rid="cimb-47-00691-f006" ref-type="fig">Figure 6</xref>B,E).</p><fig id="cimb-47-00691-f006" position="float"><?disp-level 3?><label>Figure 6</label><caption><p>Correlation of CB-Dock2 and PyrX dock docking scores with IC<sub>50</sub> of MAGL inhibition. Correlation of Vina scores of euphol and pristimerin (obtained from molecular docking using CB-Dock2) with the IC<sub>50</sub> of MAGL inhibition on (<bold>A</bold>) purified recombinant rat MAGL and (<bold>B</bold>) non-purified HeLa MAGL using data from King and colleagues [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. (<bold>C</bold>) Correlation of Vina scores of α-amyrin, β-amyrin and pristimerin with the IC<sub>50</sub> of MAGL inhibition on purified recombinant human MAGL using data from Chicca and colleagues [<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]. Correlation of PyrX dock scores of euphol and pristimerin with the IC<sub>50</sub> of MAGL inhibition on (<bold>D</bold>) purified recombinant rat MAGL and (<bold>E</bold>) non-purified HeLa MAGL using data from King and colleagues [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. (<bold>F</bold>) Correlation of PyrX dock of α-amyrin, β-amyrin and pristimerin with the IC<sub>50</sub> of MAGL inhibition on purified recombinant human.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="image" xlink:href="cimb-47-00691-g006.jpg"><?cloudpmc-path blobs/ba25/12468367/f7982f870268/cimb-47-00691-g006.jpg?><?cloudpmc-bucket cdn?><?image-server-status LOAD_COMPLETED?><?original-height 1882?><?original-width 3543?><?scaled-height 418?><?scaled-width 787?></graphic><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="thumb" xlink:href="cimb-47-00691-g006.gif"><?cloudpmc-path blobs/ba25/12468367/35f49f0d94ee/cimb-47-00691-g006.gif?><?cloudpmc-bucket cdn?></graphic></alternatives></fig><p>Pristimerin had higher binding affinity (Vina score of −11.5 kcal/mol) than β-amyrin (Vina score of −10.7 kcal/mol), and β-amyrin had higher binding affinity than α-amyrin. The binding affinity of the three triterpenes significantly correlated with the IC<sub>50</sub> of MAGL inhibition data (<italic>p</italic> &lt; 0.0001) from in vitro studies [<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]: 204 ± 16.2 nM for pristimerin, 2800 ± 500 nM for β-amyrin, and 9300 ± 1200 nM for α-amyrin on purified recombinant human MAGL (<xref rid="cimb-47-00691-f006" ref-type="fig">Figure 6</xref>C,F).</p></sec><sec id="sec3dot4-cimb-47-00691" disp-level="2"><title>3.4. Results of In Silico Prediction of Pharmacokinetic Parameters</title><p>Pharmacokinetic predictions were carried out using pkCSM (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://biosig.lab.uq.edu.au/pkcsm/" ext-link-type="uri">https://biosig.lab.uq.edu.au/pkcsm/</ext-link>) (accessed on 1 August 2025) and the results are included in <xref rid="cimb-47-00691-t0A2" ref-type="table">Table A2</xref>.</p><p>According to the predicted absorption, distribution, metabolism, excretion, and toxicity (ADMET), all compounds showed almost similar absorption properties (water solubility, Caco2 permeability, intestinal absorption, skin permeability, P-glycoprotein substrate, P-glycoprotein I inhibition, and P-glycoprotein II inhibition properties. All compounds showed high predicted intestinal permeability, as they have Caco2 permeability values &gt; 0.9. The compounds illustrated high skin permeability log Kp values. Regarding the distribution parameters, pristimerin was the only compound to show low steady state volume of distribution (VDss), which means low distribution in tissues rather than plasma. The other three compounds showed high VDss in tissues, which can be affected in the case of patients with renal failure. For the blood–brain barrier (BBB) permeability, alpha- and beta- amyrin, and euphol showed Log BB &gt; 0.3, which means they have good distribution in the brain. Pristimerin had a poor BBB permeability, which means it is poorly distributed in the brain when compared to the other three compounds. All compounds have the same predicted metabolism profile. They all have low maximum tolerated dose (&lt;0.0477 log mg/kg/day). Neither hepatotoxicity nor skin sensitization was detected in the in silico predictions.</p></sec></sec><sec id="sec4-cimb-47-00691" disp-level="1"><title>4. Discussion</title><p>MAGL is a target for managing neuropathic pain. A systematic search identified four triterpenes, α-amyrin, β-amyrin, euphol and pristimerin, that had IC<sub>50</sub> values for inhibition of MAGL activity in vitro. These four triterpenes are found in herbal plants used in ethnomedicine [<xref rid="B12-cimb-47-00691" ref-type="bibr">12</xref>,<xref rid="B15-cimb-47-00691" ref-type="bibr">15</xref>,<xref rid="B30-cimb-47-00691" ref-type="bibr">30</xref>,<xref rid="B31-cimb-47-00691" ref-type="bibr">31</xref>]. Molecular docking showed that these four triterpenes bound to the same MAGL cavity and similar amino acid residues with high affinity in the following order using docking scores (binding energy): pristimerin &gt; euphol &gt; β-amyrin &gt; α-amyrin. Simple linear regression analyses showed that there was a significant correlation between the docking scores and the IC<sub>50</sub> values for inhibition of MAGL activity, i.e., the lower the binding energy (higher affinity), the lower the IC<sub>50</sub> (more potency). The relationship of the triterpene molecules was consistent in terms of affinity, free energy of binding, and docking scores, which is an excellent computational validation of the results. MDS results showed that pristimerin had the highest stability and reached the steady state after 20 ns with lowest RMSF, especially at the binding site (docking site), when compared to the other three compounds.</p><p>The endocannabinoid 2-AG is produced on demand and rapidly metabolized by the enzyme MAGL [<xref rid="B4-cimb-47-00691" ref-type="bibr">4</xref>,<xref rid="B5-cimb-47-00691" ref-type="bibr">5</xref>,<xref rid="B6-cimb-47-00691" ref-type="bibr">6</xref>]. 2-AG has analgesic effects and alleviates neuropathic pain-related allodynia [<xref rid="B7-cimb-47-00691" ref-type="bibr">7</xref>,<xref rid="B32-cimb-47-00691" ref-type="bibr">32</xref>,<xref rid="B33-cimb-47-00691" ref-type="bibr">33</xref>]. In some models of neuropathic pain, there is a deficiency of 2-AG and increased MAGL activity [<xref rid="B7-cimb-47-00691" ref-type="bibr">7</xref>,<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>,<xref rid="B34-cimb-47-00691" ref-type="bibr">34</xref>]. Thus, inhibitors of the activity of MAGL, by increasing the levels of 2-AG, have analgesic effects, and prevent or alleviate allodynia [<xref rid="B7-cimb-47-00691" ref-type="bibr">7</xref>,<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>,<xref rid="B34-cimb-47-00691" ref-type="bibr">34</xref>]. Several MAGL inhibitors have been synthesized and most inhibit MAGL irreversibly [<xref rid="B35-cimb-47-00691" ref-type="bibr">35</xref>]. The triterpenes, such as pristimerin and euphol, inhibit MAGL reversibly and have been shown to prevent and alleviate allodynia [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>,<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. Other triterpenes, such as α-amyrin and β-amyrin, also have MAGL inhibitory activity but with less potency than pristimerin [<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]. Thus, it is possible that amongst the hundreds of triterpenes in herbal plants, there may be those with MAGL inhibitory activities. It is expensive to evaluate MAGL inhibitory effects of triterpenes in vitro; therefore, in silico screening methods such as molecular docking could be useful to screen large libraries of triterpenes for potentially active and potent congeners.</p><p>King and colleagues evaluated the MAGL inhibitory activities of pristimerin and euphol using purified recombinant rat MAGL and non-purified HeLa cell MAGL. Pristimerin and euphol were more potent in inhibiting purified recombinant rat MAGL than non-purified HeLa cell MAGL [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. Pristimerin was more potent than euphol on inhibiting both purified recombinant rat MAGL and non-purified HeLa cell MAGL [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>]. Molecular docking showed that pristimerin had lower binding energy (−11.5 and −10.83 kcal/mol), thus higher binding affinity, than euphol (−10.7 and −9.56 kcal/mol). Simple linear regression analyses showed that there was a significant correlation between the docking scores and the IC<sub>50</sub> values for inhibition of MAGL activity by pristimerin and euphol. Thus, looking at the molecular docking scores, one could predict which molecule was more potent than the other between pristimerin and euphol. Al-Romaiyan and Masocha also showed that at a concentration of 1 µm pristimerin inhibited human MAGL activity more than euphol [<xref rid="B8-cimb-47-00691" ref-type="bibr">8</xref>], in line with the IC<sub>50</sub> value relationships reported by King and colleagues [<xref rid="B10-cimb-47-00691" ref-type="bibr">10</xref>].</p><p>Chicca and colleagues evaluated the MAGL inhibitory activities of pristimerin, α-amyrin and β-amyrin using purified recombinant human MAGL. Pristimerin was more potent than β-amyrin, which was more potent than α-amyrin in inhibiting purified recombinant human MAGL [<xref rid="B11-cimb-47-00691" ref-type="bibr">11</xref>]. Molecular docking showed that pristimerin had lower binding energy (−11.5 and −10.83 kcal/mol), thus higher binding affinity, than β-amyrin (−8.8 and −8.21 kcal/mol), which had lower binding energy than α-amyrin (−8.6 and −7.95 kcal/mol). Simple linear regression analyses showed that there was a significant correlation between the docking scores and the IC<sub>50</sub> values for inhibition of MAGL activity by pristimerin, α-amyrin and β-amyrin. Thus, using molecular docking scores, one could predict which molecule would be more potent than the other amongst pristimerin, α-amyrin and β-amyrin. In addition, pristimerin, the most active compound among the tested triterpenes, exhibited a high degree of unsaturation in the A and B rings, resulting in a planar structure for this moiety, a characteristic that the other triterpenes do not share, and this could be another reason for its better activity. This characteristic needs to be further investigated.</p><p>The molecular docking studies also show that the trieterpenes interacted with the active site of MAGL. All triterpenes interacted with Ser122 of the catalytic triad, while all others except pristimerin interacted with HIS269, but none interacted with ASP239 [<xref rid="B36-cimb-47-00691" ref-type="bibr">36</xref>,<xref rid="B37-cimb-47-00691" ref-type="bibr">37</xref>]. On the oxyanion hole, which has influence on catalytic activity, all the triterpenes interacted with Gly50, Ala51, and Met123, but not Gly124 [<xref rid="B37-cimb-47-00691" ref-type="bibr">37</xref>,<xref rid="B38-cimb-47-00691" ref-type="bibr">38</xref>]. All the triterpenes interacted with PHE159 and ILE179, which are residues in the lid domain, and ALA51, ILE179, LEU213, and LEU241,which have been shown to form hydrophobic interactions with phenyl rings of inhibitors [<xref rid="B37-cimb-47-00691" ref-type="bibr">37</xref>,<xref rid="B39-cimb-47-00691" ref-type="bibr">39</xref>].</p><p>One of the limitations of this study is that only a few data points were available (IC<sub>50</sub> values of only four triterpenes) and used in each regression, and this could affect the statistical significance and predictive value of the in silico studies. However, using different computational tools and producing similar results suggests that besides limited data availability, the in silico results correlate well with the in vitro data.</p></sec><sec id="sec5-cimb-47-00691" disp-level="1"><title>5. Conclusions</title><p>The findings of this study show that molecular docking, using the CB-Dock2 server and PyRx-0.8, correlate with the potency of triterpenes found in herbal plants used in ethnomedicine and their inhibition of MAGL activity in vitro. In terms of affinity and docking scores to MAGL, pristimerin was better than euphol, which was better than β-amyrin, which was better than or equal to α-amyrin, respectively. The IC<sub>50</sub> values of recombinant human and rat MAGL inhibition found from two publications were in the following order: α-amyrin &gt; β-amyrin &gt; euphol &gt; pristimerin. Linear regression analysis showed that the affinity and docking scores significantly correlated with the IC<sub>50</sub> of MAGL inhibition. In MDS, pristimerin showed the highest stability and reached the steady state after 20 ns with the lowest RMSF at the binding site, compared to the other triterpenes. Amongst the triterpenes studied, pristimerin was the most potent inhibitor of MAGL and also had the highest affinity in the in silico studies. Thus, molecular docking could be used as a tool for virtual screening of triterpenes as MAGL inhibitors in comparison to pristimerin before wet laboratory experiments to save experimental time and costs of wet laboratory experiments. Importantly, the affinity, free energy of binding, and docking scores by both PyRx-0.8 and CB-Dock2 all showed significant correlation, which is an excellent computational validation of the results.</p></sec><sec id="app1-cimb-47-00691" sec-type="app" disp-level="1"><title>Appendix A</title><fig id="cimb-47-00691-f0A1" position="anchor"><?disp-level 2?><label>Figure A1</label><caption><p>Flow diagram of the different phases of the systematic article selection.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="image" xlink:href="cimb-47-00691-g0A1.jpg"><?cloudpmc-path blobs/ba25/12468367/013b6e58f684/cimb-47-00691-g0A1.jpg?><?cloudpmc-bucket cdn?><?image-server-status LOAD_COMPLETED?><?original-height 1507?><?original-width 2382?><?scaled-height 502?><?scaled-width 794?></graphic><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="thumb" xlink:href="cimb-47-00691-g0A1.gif"><?cloudpmc-path blobs/ba25/12468367/16c5e544a4ae/cimb-47-00691-g0A1.gif?><?cloudpmc-bucket cdn?></graphic></alternatives></fig></sec><sec id="app2-cimb-47-00691" sec-type="app" disp-level="1"><title>Appendix B</title><table-wrap id="cimb-47-00691-t0A1" position="anchor"><?disp-level 2?><label>Table A1</label><caption><p>Articles found in PubMed that were excluded from the analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Article Number</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary Reason for Exclusion</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Article Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.  </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Review article</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Review</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-cimb-47-00691" ref-type="bibr">25</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.  </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not evaluate MAGL inhibition by either pristimerin or euphol</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Original research </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-cimb-47-00691" ref-type="bibr">40</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.  </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not evaluate MAGL inhibition by either pristimerin or euphol</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Original research </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-cimb-47-00691" ref-type="bibr">41</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.  </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not evaluate MAGL inhibition by either pristimerin or euphol</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Original research </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-cimb-47-00691" ref-type="bibr">42</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.  </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Did not evaluate MAGL inhibition by either pristimerin or euphol</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Original research </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-cimb-47-00691" ref-type="bibr">43</xref>]</td></tr></tbody></table></table-wrap></sec><sec id="app3-cimb-47-00691" sec-type="app" disp-level="1"><title>Appendix C</title><table-wrap id="cimb-47-00691-t0A2" position="anchor"><?disp-level 2?><label>Table A2</label><caption><p>In silico prediction of the pharmacokinetic parameters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model Name</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">α-Amyrin</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">β-Amyrin</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Euphol</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pristimerin</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Absorption</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Water solubility (log mol/L)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−6.804</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−6.84</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−7.53</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−5.902</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caco2 permeability (log Papp in 10–6 cm/s)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.288</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.287</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.218 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.077 </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intestinal absorption (human) (% Absorbed)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.574</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.246</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.056</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin Permeability (log Kp)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−2.898</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−2.894</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−2.933</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−2.649</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-glycoprotein substrate (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-glycoprotein I inhibitor (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-glycoprotein II inhibitor (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Distribution</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VDss (human) (log L/kg)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.443</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.446</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.692</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.353</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fraction unbound (human)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BBB permeability (log BB)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.735</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.728</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.702</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.344</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CNS permeability (log PS)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−1.971</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−1.971</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−2.247</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−1.102</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Metabolism</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP2D6 substrate (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP3A4 substrate (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP1A2 inhibitor (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP2C19 inhibitor (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP2C9 inhibitor (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP2D6 inhibitor (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP3A4 inhibitor (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Execretion</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total Clearance (log mL/min/kg)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.119</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.044</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.403</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.034</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal OCT2 substrate (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<bold>Toxicity</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Max. tolerated dose (human) (log mg/kg/day)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.203</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.212</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">−0.35 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.324 </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral Rat Acute Toxicity (LD50) (mol/kg)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.156</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.169</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.867</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.234 </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral Rat Chronic Toxicity (LOAEL) (log mg/kg_bw/day)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.908</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.926</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.775</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.757 </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatotoxicity (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin Sensitisation (Yes/No)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap></sec><sec id="notes1" disp-level="1"><title>Author Contributions</title><p>Conceptualization, W.M. methodology, W.M. and M.A.K.; software, W.M. and M.A.K.; validation, W.M. and M.A.K.; formal analysis, W.M. and M.A.K.; investigation, W.M. and M.A.K.; resources, W.M. and M.A.K.; data curation, W.M. and M.A.K.; writing—original draft preparation, W.M.; writing—review and editing, W.M. and M.A.K.; project administration, W.M. All authors have read and agreed to the published version of the manuscript.</p></sec><sec id="notes2" disp-level="1"><title>Institutional Review Board Statement</title><p>Not applicable.</p></sec><sec id="notes3" disp-level="1"><title>Informed Consent Statement</title><p>Not applicable.</p></sec><sec id="notes4" disp-level="1"><title>Data Availability Statement</title><p>Data will be made available on request. The docking files have been uploaded to Zenodo. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.16890027" ext-link-type="uri">https://doi.org/10.5281/zenodo.16890027</ext-link>.</p></sec><sec id="notes5" disp-level="1"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="funding-statement1" xml:lang="en" disp-level="1"><title>Funding Statement</title><p>This research received no external funding.</p></sec><sec id="fn-group1" sec-type="fn-group" disp-level="1"><title>Footnotes</title><fn-group><fn id="fn1"><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group></sec><sec id="ref-list1" sec-type="ref-list" disp-level="1"><title>References</title><sec id="ref-list1_sec2" disp-level="2"><ref-list><ref id="B1-cimb-47-00691"><label>1.</label><mixed-citation><named-content content-type="citation-string">Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA. 2002;99:10819–10824. doi: 10.1073/pnas.152334899.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1073/pnas.152334899"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC125056"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="12136125"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Proc. Natl. Acad. Sci. USA&amp;title=Brain monoglyceride lipase participating in endocannabinoid inactivation&amp;author=T.P. Dinh&amp;author=D. Carpenter&amp;author=F.M. Leslie&amp;author=T.F. Freund&amp;author=I. Katona&amp;volume=99&amp;publication_year=2002&amp;pages=10819-10824&amp;pmid=12136125&amp;doi=10.1073/pnas.152334899&amp;"/></mixed-citation></ref><ref id="B2-cimb-47-00691"><label>2.</label><mixed-citation><named-content content-type="citation-string">Saario S.M., Savinainen J.R., Laitinen J.T., Jarvinen T., Niemi R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 2004;67:1381–1387. doi: 10.1016/j.bcp.2003.12.003.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.bcp.2003.12.003"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="15013854"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Biochem. Pharmacol.&amp;title=Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes&amp;author=S.M. Saario&amp;author=J.R. Savinainen&amp;author=J.T. Laitinen&amp;author=T. Jarvinen&amp;author=R. Niemi&amp;volume=67&amp;publication_year=2004&amp;pages=1381-1387&amp;pmid=15013854&amp;doi=10.1016/j.bcp.2003.12.003&amp;"/></mixed-citation></ref><ref id="B3-cimb-47-00691"><label>3.</label><mixed-citation><named-content content-type="citation-string">Zou S., Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci. 2018;19:833.  doi: 10.3390/ijms19030833.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3390/ijms19030833"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC5877694"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29533978"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Int. J. Mol. Sci.&amp;title=Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System&amp;author=S. Zou&amp;author=U. Kumar&amp;volume=19&amp;publication_year=2018&amp;pages=833&amp;pmid=29533978&amp;doi=10.3390/ijms19030833&amp;"/></mixed-citation></ref><ref id="B4-cimb-47-00691"><label>4.</label><mixed-citation><named-content content-type="citation-string">Chen C. Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. Pharmacol. Ther. 2023;244:108394. doi: 10.1016/j.pharmthera.2023.108394.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.pharmthera.2023.108394"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC10123871"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="36966972"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Pharmacol. Ther.&amp;title=Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases&amp;author=C. Chen&amp;volume=244&amp;publication_year=2023&amp;pages=108394&amp;pmid=36966972&amp;doi=10.1016/j.pharmthera.2023.108394&amp;"/></mixed-citation></ref><ref id="B5-cimb-47-00691"><label>5.</label><mixed-citation><named-content content-type="citation-string">Sugiura T., Kishimoto S., Oka S., Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 2006;45:405–446. doi: 10.1016/j.plipres.2006.03.003.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.plipres.2006.03.003"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="16678907"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Prog. Lipid Res.&amp;title=Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand&amp;author=T. Sugiura&amp;author=S. Kishimoto&amp;author=S. Oka&amp;author=M. Gokoh&amp;volume=45&amp;publication_year=2006&amp;pages=405-446&amp;pmid=16678907&amp;doi=10.1016/j.plipres.2006.03.003&amp;"/></mixed-citation></ref><ref id="B6-cimb-47-00691"><label>6.</label><mixed-citation><named-content content-type="citation-string">Hashimotodani Y., Ohno-Shosaku T., Tanimura A., Kita Y., Sano Y., Shimizu T., Di Marzo V., Kano M. Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde signalling: Evidence for on-demand biosynthesis of 2-arachidonoylglycerol. J. Physiol. 2013;591:4765–4776. doi: 10.1113/jphysiol.2013.254474.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1113/jphysiol.2013.254474"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC3800453"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="23858009"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=J. Physiol.&amp;title=Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde signalling: Evidence for on-demand biosynthesis of 2-arachidonoylglycerol&amp;author=Y. Hashimotodani&amp;author=T. Ohno-Shosaku&amp;author=A. Tanimura&amp;author=Y. Kita&amp;author=Y. Sano&amp;volume=591&amp;publication_year=2013&amp;pages=4765-4776&amp;pmid=23858009&amp;doi=10.1113/jphysiol.2013.254474&amp;"/></mixed-citation></ref><ref id="B7-cimb-47-00691"><label>7.</label><mixed-citation><named-content content-type="citation-string">Thomas A., Okine B.N., Finn D.P., Masocha W. Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain. Biomed. Pharmacother. 2020;129:110456.  doi: 10.1016/j.biopha.2020.110456.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.biopha.2020.110456"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="32603895"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Biomed. Pharmacother.&amp;title=Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain&amp;author=A. Thomas&amp;author=B.N. Okine&amp;author=D.P. Finn&amp;author=W. Masocha&amp;volume=129&amp;publication_year=2020&amp;pages=110456&amp;pmid=32603895&amp;doi=10.1016/j.biopha.2020.110456&amp;"/></mixed-citation></ref><ref id="B8-cimb-47-00691"><label>8.</label><mixed-citation><named-content content-type="citation-string">Al-Romaiyan A., Masocha W. Pristimerin, a triterpene that inhibits monoacylglycerol lipase activity, prevents the development of paclitaxel-induced allodynia in mice. Front. Pharmacol. 2022;13:944502.  doi: 10.3389/fphar.2022.944502.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3389/fphar.2022.944502"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC9395968"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="36016571"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Front. Pharmacol.&amp;title=Pristimerin, a triterpene that inhibits monoacylglycerol lipase activity, prevents the development of paclitaxel-induced allodynia in mice&amp;author=A. Al-Romaiyan&amp;author=W. Masocha&amp;volume=13&amp;publication_year=2022&amp;pages=944502&amp;pmid=36016571&amp;doi=10.3389/fphar.2022.944502&amp;"/></mixed-citation></ref><ref id="B9-cimb-47-00691"><label>9.</label><mixed-citation><named-content content-type="citation-string">Curry Z.A., Wilkerson J.L., Bagdas D., Kyte S.L., Patel N., Donvito G., Mustafa M.A., Poklis J.L., Niphakis M.J., Hsu K.L., et al.  Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy. J. Pharmacol. Exp. Ther. 2018;366:169–183. doi: 10.1124/jpet.117.245704.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1124/jpet.117.245704"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC6038031"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29540562"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=J. Pharmacol. Exp. Ther.&amp;title=Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy&amp;author=Z.A. Curry&amp;author=J.L. Wilkerson&amp;author=D. Bagdas&amp;author=S.L. Kyte&amp;author=N. Patel&amp;volume=366&amp;publication_year=2018&amp;pages=169-183&amp;pmid=29540562&amp;doi=10.1124/jpet.117.245704&amp;"/></mixed-citation></ref><ref id="B10-cimb-47-00691"><label>10.</label><mixed-citation><named-content content-type="citation-string">King A.R., Dotsey E.Y., Lodola A., Jung K.M., Ghomian A., Qiu Y., Fu J., Mor M., Piomelli D. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem. Biol. 2009;16:1045–1052. doi: 10.1016/j.chembiol.2009.09.012.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.chembiol.2009.09.012"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC3034734"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="19875078"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Chem. Biol.&amp;title=Discovery of potent and reversible monoacylglycerol lipase inhibitors&amp;author=A.R. King&amp;author=E.Y. Dotsey&amp;author=A. Lodola&amp;author=K.M. Jung&amp;author=A. Ghomian&amp;volume=16&amp;publication_year=2009&amp;pages=1045-1052&amp;pmid=19875078&amp;doi=10.1016/j.chembiol.2009.09.012&amp;"/></mixed-citation></ref><ref id="B11-cimb-47-00691"><label>11.</label><mixed-citation><named-content content-type="citation-string">Chicca A., Marazzi J., Gertsch J. The antinociceptive triterpene beta-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. Br. J. Pharmacol. 2012;167:1596–1608. doi: 10.1111/j.1476-5381.2012.02059.x.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1111/j.1476-5381.2012.02059.x"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC3525863"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="22646533"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Br. J. Pharmacol.&amp;title=The antinociceptive triterpene beta-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors&amp;author=A. Chicca&amp;author=J. Marazzi&amp;author=J. Gertsch&amp;volume=167&amp;publication_year=2012&amp;pages=1596-1608&amp;pmid=22646533&amp;doi=10.1111/j.1476-5381.2012.02059.x&amp;"/></mixed-citation></ref><ref id="B12-cimb-47-00691"><label>12.</label><mixed-citation><named-content content-type="citation-string">Shen J., Kai J., Tang Y., Zhang L., Su S., Duan J.A. The Chemical and Biological Properties of Euphorbia kansui. Am. J. Chin. Med. 2016;44:253–273. doi: 10.1142/S0192415X16500154.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1142/S0192415X16500154"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="27080940"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Am. J. Chin. Med.&amp;title=The Chemical and Biological Properties of Euphorbia kansui&amp;author=J. Shen&amp;author=J. Kai&amp;author=Y. Tang&amp;author=L. Zhang&amp;author=S. Su&amp;volume=44&amp;publication_year=2016&amp;pages=253-273&amp;pmid=27080940&amp;doi=10.1142/S0192415X16500154&amp;"/></mixed-citation></ref><ref id="B13-cimb-47-00691"><label>13.</label><mixed-citation><named-content content-type="citation-string">Yuan X., Yan Q., Hu H., He X.-P., Wang L.-X., Liu Y.-C., Liu Y., Guo K., Li S.-H. Bioactive triterpenoids from the traditional Chinese medicine Swertia mileensis. Phytochem. Lett. 2023;55:1–5. doi: 10.1016/j.phytol.2023.03.001.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.phytol.2023.03.001"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Phytochem. Lett.&amp;title=Bioactive triterpenoids from the traditional Chinese medicine Swertia mileensis&amp;author=X. Yuan&amp;author=Q. Yan&amp;author=H. Hu&amp;author=X.-P. He&amp;author=L.-X. Wang&amp;volume=55&amp;publication_year=2023&amp;pages=1-5&amp;doi=10.1016/j.phytol.2023.03.001&amp;"/></mixed-citation></ref><ref id="B14-cimb-47-00691"><label>14.</label><mixed-citation><named-content content-type="citation-string">Zhang L., Xu Z.J., Feng Y.J., Wang D.Y. Chemical constituents of roots of Celastrus orbiculatus. Zhong Yao Cai. 2013;36:569–572.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="24134003"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Zhong Yao Cai&amp;title=Chemical constituents of roots of Celastrus orbiculatus&amp;author=L. Zhang&amp;author=Z.J. Xu&amp;author=Y.J. Feng&amp;author=D.Y. Wang&amp;volume=36&amp;publication_year=2013&amp;pages=569-572&amp;pmid=24134003&amp;"/></mixed-citation></ref><ref id="B15-cimb-47-00691"><label>15.</label><mixed-citation><named-content content-type="citation-string">Zhang Q., Zhou Q.R., Lou J.W., Chen P.D., Yao W.F., Tao W.W., Tang Y.P., Dai G.C., Wang K., Zhang L. Chemical Constituents from Euphorbia kansui. Molecules. 2017;22:2176.  doi: 10.3390/molecules22122176.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3390/molecules22122176"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC6150036"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29292735"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Molecules&amp;title=Chemical Constituents from Euphorbia kansui&amp;author=Q. Zhang&amp;author=Q.R. Zhou&amp;author=J.W. Lou&amp;author=P.D. Chen&amp;author=W.F. Yao&amp;volume=22&amp;publication_year=2017&amp;pages=2176&amp;pmid=29292735&amp;doi=10.3390/molecules22122176&amp;"/></mixed-citation></ref><ref id="B16-cimb-47-00691"><label>16.</label><mixed-citation><named-content content-type="citation-string">Zhuo Y., Li M., Jiang Q., Ke H., Liang Q., Zeng L.F., Fang J. Evolving Roles of Natural Terpenoids From Traditional Chinese Medicine in the Treatment of Osteoporosis. Front. Endocrinol. 2022;13:901545.  doi: 10.3389/fendo.2022.901545.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3389/fendo.2022.901545"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC9150774"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="35651977"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Front. Endocrinol.&amp;title=Evolving Roles of Natural Terpenoids From Traditional Chinese Medicine in the Treatment of Osteoporosis&amp;author=Y. Zhuo&amp;author=M. Li&amp;author=Q. Jiang&amp;author=H. Ke&amp;author=Q. Liang&amp;volume=13&amp;publication_year=2022&amp;pages=901545&amp;pmid=35651977&amp;doi=10.3389/fendo.2022.901545&amp;"/></mixed-citation></ref><ref id="B17-cimb-47-00691"><label>17.</label><mixed-citation><named-content content-type="citation-string">Dutra R.C., Simao da Silva K.A., Bento A.F., Marcon R., Paszcuk A.F., Meotti F.C., Pianowski L.F., Calixto J.B. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: The involvement of cannabinoid system. Neuropharmacology. 2012;63:593–605. doi: 10.1016/j.neuropharm.2012.05.008.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.neuropharm.2012.05.008"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="22613837"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Neuropharmacology&amp;title=Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: The involvement of cannabinoid system&amp;author=R.C. Dutra&amp;author=K.A. Simao da Silva&amp;author=A.F. Bento&amp;author=R. Marcon&amp;author=A.F. Paszcuk&amp;volume=63&amp;publication_year=2012&amp;pages=593-605&amp;pmid=22613837&amp;doi=10.1016/j.neuropharm.2012.05.008&amp;"/></mixed-citation></ref><ref id="B18-cimb-47-00691"><label>18.</label><mixed-citation><named-content content-type="citation-string">Maia J.L., Lima-Junior R.C., Melo C.M., David J.P., David J.M., Campos A.R., Santos F.A., Rao V.S. Oleanolic acid, a pentacyclic triterpene attenuates capsaicin-induced nociception in mice: Possible mechanisms. Pharmacol. Res. 2006;54:282–286. doi: 10.1016/j.phrs.2006.06.003.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.phrs.2006.06.003"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="16879974"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Pharmacol. Res.&amp;title=Oleanolic acid, a pentacyclic triterpene attenuates capsaicin-induced nociception in mice: Possible mechanisms&amp;author=J.L. Maia&amp;author=R.C. Lima-Junior&amp;author=C.M. Melo&amp;author=J.P. David&amp;author=J.M. David&amp;volume=54&amp;publication_year=2006&amp;pages=282-286&amp;pmid=16879974&amp;doi=10.1016/j.phrs.2006.06.003&amp;"/></mixed-citation></ref><ref id="B19-cimb-47-00691"><label>19.</label><mixed-citation><named-content content-type="citation-string">Dato F.M., Neudorfl J.M., Gutschow M., Goldfuss B., Pietsch M. omega-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase. Bioorg. Chem. 2020;94:103352.  doi: 10.1016/j.bioorg.2019.103352.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.bioorg.2019.103352"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="31668797"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Bioorg. Chem.&amp;title=omega-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase&amp;author=F.M. Dato&amp;author=J.M. Neudorfl&amp;author=M. Gutschow&amp;author=B. Goldfuss&amp;author=M. Pietsch&amp;volume=94&amp;publication_year=2020&amp;pages=103352&amp;pmid=31668797&amp;doi=10.1016/j.bioorg.2019.103352&amp;"/></mixed-citation></ref><ref id="B20-cimb-47-00691"><label>20.</label><mixed-citation><named-content content-type="citation-string">Di Stefano M., Masoni S., Bononi G., Poli G., Galati S., Gado F., Manzi S., Vagaggini C., Brai A., Caligiuri I., et al.  Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors. Eur. J. Med. Chem. 2024;263:115916. doi: 10.1016/j.ejmech.2023.115916.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.ejmech.2023.115916"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="37976705"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Eur. J. Med. Chem.&amp;title=Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors&amp;author=M. Di Stefano&amp;author=S. Masoni&amp;author=G. Bononi&amp;author=G. Poli&amp;author=S. Galati&amp;volume=263&amp;publication_year=2024&amp;pages=115916&amp;pmid=37976705&amp;doi=10.1016/j.ejmech.2023.115916&amp;"/></mixed-citation></ref><ref id="B21-cimb-47-00691"><label>21.</label><mixed-citation><named-content content-type="citation-string">Hernandez-Torres G., Cipriano M., Heden E., Bjorklund E., Canales A., Zian D., Feliu A., Mecha M., Guaza C., Fowler C.J., et al.  A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew. Chem. Int. Ed. Engl. 2014;53:13765–13770. doi: 10.1002/anie.201407807.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1002/anie.201407807"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="25298214"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Angew. Chem. Int. Ed. Engl.&amp;title=A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis&amp;author=G. Hernandez-Torres&amp;author=M. Cipriano&amp;author=E. Heden&amp;author=E. Bjorklund&amp;author=A. Canales&amp;volume=53&amp;publication_year=2014&amp;pages=13765-13770&amp;pmid=25298214&amp;doi=10.1002/anie.201407807&amp;"/></mixed-citation></ref><ref id="B22-cimb-47-00691"><label>22.</label><mixed-citation><named-content content-type="citation-string">Kochnev Y., Ahmed M., Maldonado A.M., Durrant J.D. MolModa: Accessible and secure molecular docking in a web browser. Nucleic Acids Res. 2024;52:W498–W506. doi: 10.1093/nar/gkae406.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1093/nar/gkae406"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC11223821"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="38783339"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Nucleic Acids Res.&amp;title=MolModa: Accessible and secure molecular docking in a web browser&amp;author=Y. Kochnev&amp;author=M. Ahmed&amp;author=A.M. Maldonado&amp;author=J.D. Durrant&amp;volume=52&amp;publication_year=2024&amp;pages=W498-W506&amp;pmid=38783339&amp;doi=10.1093/nar/gkae406&amp;"/></mixed-citation></ref><ref id="B23-cimb-47-00691"><label>23.</label><mixed-citation><named-content content-type="citation-string">Liu Y., Cao Y. Protein-Ligand Blind Docking Using CB-Dock2. Methods Mol. Biol. 2024;2714:113–125. doi: 10.1007/978-1-0716-3441-7_6.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1007/978-1-0716-3441-7_6"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="37676595"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Methods Mol. Biol.&amp;title=Protein-Ligand Blind Docking Using CB-Dock2&amp;author=Y. Liu&amp;author=Y. Cao&amp;volume=2714&amp;publication_year=2024&amp;pages=113-125&amp;pmid=37676595&amp;doi=10.1007/978-1-0716-3441-7_6&amp;"/></mixed-citation></ref><ref id="B24-cimb-47-00691"><label>24.</label><mixed-citation><named-content content-type="citation-string">Singh N., Chaput L., Villoutreix B.O. Virtual screening web servers: Designing chemical probes and drug candidates in the cyberspace. Brief. Bioinform. 2021;22:1790–1818. doi: 10.1093/bib/bbaa034.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1093/bib/bbaa034"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC7986591"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="32187356"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Brief. Bioinform.&amp;title=Virtual screening web servers: Designing chemical probes and drug candidates in the cyberspace&amp;author=N. Singh&amp;author=L. Chaput&amp;author=B.O. Villoutreix&amp;volume=22&amp;publication_year=2021&amp;pages=1790-1818&amp;pmid=32187356&amp;doi=10.1093/bib/bbaa034&amp;"/></mixed-citation></ref><ref id="B25-cimb-47-00691"><label>25.</label><mixed-citation><named-content content-type="citation-string">Masocha W., Aly E., Albaloushi A., Al-Romaiyan A. Licofelone, a Dual COX/LOX Inhibitor, Ameliorates Paclitaxel-Induced Mechanical Allodynia in Rats in a Cannabinoid Receptor-Dependent Manner. Biomedicines. 2024;12:1545.  doi: 10.3390/biomedicines12071545.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3390/biomedicines12071545"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC11274467"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="39062118"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Biomedicines&amp;title=Licofelone, a Dual COX/LOX Inhibitor, Ameliorates Paclitaxel-Induced Mechanical Allodynia in Rats in a Cannabinoid Receptor-Dependent Manner&amp;author=W. Masocha&amp;author=E. Aly&amp;author=A. Albaloushi&amp;author=A. Al-Romaiyan&amp;volume=12&amp;publication_year=2024&amp;pages=1545&amp;pmid=39062118&amp;doi=10.3390/biomedicines12071545&amp;"/></mixed-citation></ref><ref id="B26-cimb-47-00691"><label>26.</label><mixed-citation><named-content content-type="citation-string">Bugnon M., Rohrig U.F., Goullieux M., Perez M.A.S., Daina A., Michielin O., Zoete V. SwissDock 2024: Major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina. Nucleic Acids Res. 2024;52:W324–W332. doi: 10.1093/nar/gkae300.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1093/nar/gkae300"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC11223881"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="38686803"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Nucleic Acids Res.&amp;title=SwissDock 2024: Major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina&amp;author=M. Bugnon&amp;author=U.F. Rohrig&amp;author=M. Goullieux&amp;author=M.A.S. Perez&amp;author=A. Daina&amp;volume=52&amp;publication_year=2024&amp;pages=W324-W332&amp;pmid=38686803&amp;doi=10.1093/nar/gkae300&amp;"/></mixed-citation></ref><ref id="B27-cimb-47-00691"><label>27.</label><mixed-citation><named-content content-type="citation-string">Eberhardt J., Santos-Martins D., Tillack A.F., Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J. Chem. Inf. Model. 2021;61:3891–3898. doi: 10.1021/acs.jcim.1c00203.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1021/acs.jcim.1c00203"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC10683950"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="34278794"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=J. Chem. Inf. Model.&amp;title=AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings&amp;author=J. Eberhardt&amp;author=D. Santos-Martins&amp;author=A.F. Tillack&amp;author=S. Forli&amp;volume=61&amp;publication_year=2021&amp;pages=3891-3898&amp;pmid=34278794&amp;doi=10.1021/acs.jcim.1c00203&amp;"/></mixed-citation></ref><ref id="B28-cimb-47-00691"><label>28.</label><mixed-citation><named-content content-type="citation-string">Dallakyan S., Olson A.J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 2015;1263:243–250. doi: 10.1007/978-1-4939-2269-7_19.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1007/978-1-4939-2269-7_19"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="25618350"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Methods Mol. Biol.&amp;title=Small-molecule library screening by docking with PyRx&amp;author=S. Dallakyan&amp;author=A.J. Olson&amp;volume=1263&amp;publication_year=2015&amp;pages=243-250&amp;pmid=25618350&amp;doi=10.1007/978-1-4939-2269-7_19&amp;"/></mixed-citation></ref><ref id="B29-cimb-47-00691"><label>29.</label><mixed-citation><named-content content-type="citation-string">Soliman A.M., Ghorab M.M., Higgins M., Dinkova-Kostova A.T., Korany M., Amin M.A., Khedr M.A., Sakr T.M. NQO1 induction and radiation-based biodistribution study of a new quinoline derivative identified in a screen of 6,8-diiodoquinazolinone sulfonamide conjugates. Eur. J. Med. Chem. 2025;296:117855. doi: 10.1016/j.ejmech.2025.117855.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.ejmech.2025.117855"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="40554306"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Eur. J. Med. Chem.&amp;title=NQO1 induction and radiation-based biodistribution study of a new quinoline derivative identified in a screen of 6,8-diiodoquinazolinone sulfonamide conjugates&amp;author=A.M. Soliman&amp;author=M.M. Ghorab&amp;author=M. Higgins&amp;author=A.T. Dinkova-Kostova&amp;author=M. Korany&amp;volume=296&amp;publication_year=2025&amp;pages=117855&amp;pmid=40554306&amp;doi=10.1016/j.ejmech.2025.117855&amp;"/></mixed-citation></ref><ref id="B30-cimb-47-00691"><label>30.</label><mixed-citation><named-content content-type="citation-string">Chen R.Z., Yang F., Zhang M., Sun Z.G., Zhang N. Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances. Front. Oncol. 2021;11:671548.  doi: 10.3389/fonc.2021.671548.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3389/fonc.2021.671548"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC8138054"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="34026649"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Front. Oncol.&amp;title=Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances&amp;author=R.Z. Chen&amp;author=F. Yang&amp;author=M. Zhang&amp;author=Z.G. Sun&amp;author=N. Zhang&amp;volume=11&amp;publication_year=2021&amp;pages=671548&amp;pmid=34026649&amp;doi=10.3389/fonc.2021.671548&amp;"/></mixed-citation></ref><ref id="B31-cimb-47-00691"><label>31.</label><mixed-citation><named-content content-type="citation-string">Sun J., Tian Z., Wu J., Li J., Wang Q., Huang S., Wang M. Pristimerin Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review. Drug Des. Devel. Ther. 2024;18:1673–1694. doi: 10.2147/DDDT.S460093.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.2147/DDDT.S460093"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC11110813"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="38779590"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Drug Des. Devel. Ther.&amp;title=Pristimerin Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review&amp;author=J. Sun&amp;author=Z. Tian&amp;author=J. Wu&amp;author=J. Li&amp;author=Q. Wang&amp;volume=18&amp;publication_year=2024&amp;pages=1673-1694&amp;pmid=38779590&amp;doi=10.2147/DDDT.S460093&amp;"/></mixed-citation></ref><ref id="B32-cimb-47-00691"><label>32.</label><mixed-citation><named-content content-type="citation-string">Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995;50:83–90. doi: 10.1016/0006-2952(95)00109-D.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/0006-2952(95)00109-D"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="7605349"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Biochem. Pharmacol.&amp;title=Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors&amp;author=R. Mechoulam&amp;author=S. Ben-Shabat&amp;author=L. Hanus&amp;author=M. Ligumsky&amp;author=N.E. Kaminski&amp;volume=50&amp;publication_year=1995&amp;pages=83-90&amp;pmid=7605349&amp;doi=10.1016/0006-2952(95)00109-D&amp;"/></mixed-citation></ref><ref id="B33-cimb-47-00691"><label>33.</label><mixed-citation><named-content content-type="citation-string">Munawar N., Oriowo M.A., Masocha W. Antihyperalgesic Activities of Endocannabinoids in a Mouse Model of Antiretroviral-Induced Neuropathic Pain. Front. Pharmacol. 2017;8:136.  doi: 10.3389/fphar.2017.00136.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3389/fphar.2017.00136"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC5357623"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="28373843"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Front. Pharmacol.&amp;title=Antihyperalgesic Activities of Endocannabinoids in a Mouse Model of Antiretroviral-Induced Neuropathic Pain&amp;author=N. Munawar&amp;author=M.A. Oriowo&amp;author=W. Masocha&amp;volume=8&amp;publication_year=2017&amp;pages=136&amp;pmid=28373843&amp;doi=10.3389/fphar.2017.00136&amp;"/></mixed-citation></ref><ref id="B34-cimb-47-00691"><label>34.</label><mixed-citation><named-content content-type="citation-string">Guindon J., Lai Y., Takacs S.M., Bradshaw H.B., Hohmann A.G. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol. Res. 2013;67:94–109. doi: 10.1016/j.phrs.2012.10.013.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.phrs.2012.10.013"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC3525790"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="23127915"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Pharmacol. Res.&amp;title=Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment&amp;author=J. Guindon&amp;author=Y. Lai&amp;author=S.M. Takacs&amp;author=H.B. Bradshaw&amp;author=A.G. Hohmann&amp;volume=67&amp;publication_year=2013&amp;pages=94-109&amp;pmid=23127915&amp;doi=10.1016/j.phrs.2012.10.013&amp;"/></mixed-citation></ref><ref id="B35-cimb-47-00691"><label>35.</label><mixed-citation><named-content content-type="citation-string">Scalvini L., Piomelli D., Mor M. Monoglyceride lipase: Structure and inhibitors. Chem. Phys. Lipids. 2016;197:13–24. doi: 10.1016/j.chemphyslip.2015.07.011.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.chemphyslip.2015.07.011"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC4728057"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="26216043"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Chem. Phys. Lipids&amp;title=Monoglyceride lipase: Structure and inhibitors&amp;author=L. Scalvini&amp;author=D. Piomelli&amp;author=M. Mor&amp;volume=197&amp;publication_year=2016&amp;pages=13-24&amp;pmid=26216043&amp;doi=10.1016/j.chemphyslip.2015.07.011&amp;"/></mixed-citation></ref><ref id="B36-cimb-47-00691"><label>36.</label><mixed-citation><named-content content-type="citation-string">Karlsson M., Contreras J.A., Hellman U., Tornqvist H., Holm C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J. Biol. Chem. 1997;272:27218–27223. doi: 10.1074/jbc.272.43.27218.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1074/jbc.272.43.27218"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="9341166"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=J. Biol. Chem.&amp;title=cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases&amp;author=M. Karlsson&amp;author=J.A. Contreras&amp;author=U. Hellman&amp;author=H. Tornqvist&amp;author=C. Holm&amp;volume=272&amp;publication_year=1997&amp;pages=27218-27223&amp;pmid=9341166&amp;doi=10.1074/jbc.272.43.27218&amp;"/></mixed-citation></ref><ref id="B37-cimb-47-00691"><label>37.</label><mixed-citation><named-content content-type="citation-string">Liu C., Guan S., E J., Yang Z., Zhang X., Ju J., Wang S., Zhang H. Insight into the Inhibitory Mechanism of Aryl Formyl Piperidine Derivatives on Monoacylglycerol Lipase through Molecular Dynamics Simulations. Molecules. 2022;27:7512.  doi: 10.3390/molecules27217512.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.3390/molecules27217512"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC9655140"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="36364337"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Molecules&amp;title=Insight into the Inhibitory Mechanism of Aryl Formyl Piperidine Derivatives on Monoacylglycerol Lipase through Molecular Dynamics Simulations&amp;author=C. Liu&amp;author=S. Guan&amp;author=J. E&amp;author=Z. Yang&amp;author=X. Zhang&amp;volume=27&amp;publication_year=2022&amp;pages=7512&amp;pmid=36364337&amp;doi=10.3390/molecules27217512&amp;"/></mixed-citation></ref><ref id="B38-cimb-47-00691"><label>38.</label><mixed-citation><named-content content-type="citation-string">Afzal O., Kumar S., Kumar R., Firoz A., Jaggi M., Bawa S. Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors. Bioorg. Med. Chem. Lett. 2014;24:3986–3996. doi: 10.1016/j.bmcl.2014.06.029.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.bmcl.2014.06.029"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="25011912"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Bioorg. Med. Chem. Lett.&amp;title=Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors&amp;author=O. Afzal&amp;author=S. Kumar&amp;author=R. Kumar&amp;author=A. Firoz&amp;author=M. Jaggi&amp;volume=24&amp;publication_year=2014&amp;pages=3986-3996&amp;pmid=25011912&amp;doi=10.1016/j.bmcl.2014.06.029&amp;"/></mixed-citation></ref><ref id="B39-cimb-47-00691"><label>39.</label><mixed-citation><named-content content-type="citation-string">Jha V., Galati S., Volpi V., Ciccone L., Minutolo F., Rizzolio F., Granchi C., Poli G., Tuccinardi T. Discovery of a new ATP-citrate lyase (ACLY) inhibitor identified by a pharmacophore-based virtual screening study. J. Biomol. Struct. Dyn. 2021;39:3996–4004. doi: 10.1080/07391102.2020.1773314.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1080/07391102.2020.1773314"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="32448086"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=J. Biomol. Struct. Dyn.&amp;title=Discovery of a new ATP-citrate lyase (ACLY) inhibitor identified by a pharmacophore-based virtual screening study&amp;author=V. Jha&amp;author=S. Galati&amp;author=V. Volpi&amp;author=L. Ciccone&amp;author=F. Minutolo&amp;volume=39&amp;publication_year=2021&amp;pages=3996-4004&amp;pmid=32448086&amp;doi=10.1080/07391102.2020.1773314&amp;"/></mixed-citation></ref><ref id="B40-cimb-47-00691"><label>40.</label><mixed-citation><named-content content-type="citation-string">Parkkari T., Haavikko R., Laitinen T., Navia-Paldanius D., Rytilahti R., Vaara M., Lehtonen M., Alakurtti S., Yli-Kauhaluoma J., Nevalainen T., et al.  Discovery of triterpenoids as reversible inhibitors of alpha/beta-hydrolase domain containing 12 (ABHD12) PLoS ONE. 2014;9:e98286.  doi: 10.1371/journal.pone.0098286.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1371/journal.pone.0098286"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmcid" xlink:href="PMC4045134"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="24879289"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=PLoS ONE&amp;title=Discovery of triterpenoids as reversible inhibitors of alpha/beta-hydrolase domain containing 12 (ABHD12)&amp;author=T. Parkkari&amp;author=R. Haavikko&amp;author=T. Laitinen&amp;author=D. Navia-Paldanius&amp;author=R. Rytilahti&amp;volume=9&amp;publication_year=2014&amp;pages=e98286&amp;pmid=24879289&amp;doi=10.1371/journal.pone.0098286&amp;"/></mixed-citation></ref><ref id="B41-cimb-47-00691"><label>41.</label><mixed-citation><named-content content-type="citation-string">Benabdelaziz I., Gomez-Ruiz S., Benkhaled M., Carralero S., Schenker P., Salm A., Gertsch J., Haba H. New cycloartane-type ester triterpenes from Euphorbia pterococca and biological evaluation. Fitoterapia. 2018;127:271–278. doi: 10.1016/j.fitote.2018.02.027.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.fitote.2018.02.027"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29524564"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Fitoterapia&amp;title=New cycloartane-type ester triterpenes from Euphorbia pterococca and biological evaluation&amp;author=I. Benabdelaziz&amp;author=S. Gomez-Ruiz&amp;author=M. Benkhaled&amp;author=S. Carralero&amp;author=P. Schenker&amp;volume=127&amp;publication_year=2018&amp;pages=271-278&amp;pmid=29524564&amp;doi=10.1016/j.fitote.2018.02.027&amp;"/></mixed-citation></ref><ref id="B42-cimb-47-00691"><label>42.</label><mixed-citation><named-content content-type="citation-string">Veloso C.C., Ferreira R.C.M., Rodrigues V.G., Duarte L.P., Klein A., Duarte I.D., Romero T.R.L., Perez A.C. Tingenone, a pentacyclic triterpene, induces peripheral antinociception due to cannabinoid receptors activation in mice. Inflammopharmacology. 2018;26:227–233. doi: 10.1007/s10787-017-0391-7.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1007/s10787-017-0391-7"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="28889355"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=Inflammopharmacology&amp;title=Tingenone, a pentacyclic triterpene, induces peripheral antinociception due to cannabinoid receptors activation in mice&amp;author=C.C. Veloso&amp;author=R.C.M. Ferreira&amp;author=V.G. Rodrigues&amp;author=L.P. Duarte&amp;author=A. Klein&amp;volume=26&amp;publication_year=2018&amp;pages=227-233&amp;pmid=28889355&amp;doi=10.1007/s10787-017-0391-7&amp;"/></mixed-citation></ref><ref id="B43-cimb-47-00691"><label>43.</label><mixed-citation><named-content content-type="citation-string">Merali Z., Cayer C., Kent P., Liu R., Cal V., Harris C.S., Arnason J.T. Sacred Maya incense, copal (Protium copal-Burseraceae), has antianxiety effects in animal models. J. Ethnopharmacol. 2018;216:63–70. doi: 10.1016/j.jep.2018.01.027.</named-content><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.jep.2018.01.027"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29414121"/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="google-scholar" xlink:href="journal=J. Ethnopharmacol.&amp;title=Sacred Maya incense, copal (Protium copal-Burseraceae), has antianxiety effects in animal models&amp;author=Z. Merali&amp;author=C. Cayer&amp;author=P. Kent&amp;author=R. Liu&amp;author=V. Cal&amp;volume=216&amp;publication_year=2018&amp;pages=63-70&amp;pmid=29414121&amp;doi=10.1016/j.jep.2018.01.027&amp;"/></mixed-citation></ref></ref-list></sec></sec><sec id="_ad93_" xml:lang="en" sec-type="associated-data" disp-level="1"><title>Associated Data</title><sec id="_adda93_" xml:lang="en" sec-type="data-availability-statement" disp-level="2"><title>Data Availability Statement</title><p>Data will be made available on request. The docking files have been uploaded to Zenodo. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.5281/zenodo.16890027" ext-link-type="uri">https://doi.org/10.5281/zenodo.16890027</ext-link>.</p></sec></sec></body></article>